Abstract
Background: To investigate the relationship between visfatin level in the peripheral blood of patients with acute myocardial infarction (AMI) patients and the severity of AMI, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention (PCI).
Methods: A total of 37 AMI patients diagnosed and treated in our hospital were selected as experimental group, and 35 patients with normal coronary angiography were enrolled as control group. The general pathological data and occurrence of atrial fibrillation after PCI of all the patients were recorded in detail, and the content of indexes related to the severity of AMI and visfatin was measured. Moreover, the correlations of visfatin with the severity of AMI, cardiovascular risk factors and atrial fibrillation after PCI were explored.
Results: The differences in the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), myoglobin (MYO) and creatine kinase isoenzyme MB mass (CK-MBm) in the peripheral blood, left ventricular end-systolic diameter (LVEDs), left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF) were statistically significant between experimental group and control group. Furthermore, experimental group had a remarkably higher visfatin level in the peripheral blood than control group. The visfatin level in the peripheral blood was positively correlated with the severity of AMI and the cardiovascular risk factors, but it was negatively associated with atrial fibrillation after PCI.
Conclusion: The visfatin level in the peripheral blood of AMI patients has close correlations with the severity of AMI, cardiovascular risk factors and atrial fibrillation after PCI.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.